US FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavir
Under the existing agreement, injectable lenacapavir will be available at US$40 per person per year across 120 countries covered…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lenacapavir
Dr. Reddy’s expands collaboration with Gilead Sciences for investigational once-yearly…
Dr. Reddy's Laboratories announced a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for…
Gilead Sciences signs licencing agreements with six companies to manufacture, commercialise…
Dr Reddy’s Laboratories, Emcure Pharma, Hetero Drugs and Mylan Labs (a subsidiary of Viatris), are among the six companies that…
Merck to initiate new clinical programme with lower dose of daily oral Islatravir in combination…
Phase-II study evaluating an investigational weekly oral combination treatment regimen of Islatravir and Gilead Sciences’…
EMA validates Gilead’s Marketing Authorisation Application for Lenacapavir
Lenacapavir is an investigational, long-acting capsid inhibitor for the treatment of HIV-1 in people with limited therapy options
Gilead and Merck initiate phase-II study on Lenacapavir and Islatravir oral combo for HIV-1…
This clinical study is the first from Merck and Gilead’s collaboration to develop potential long-acting HIV treatment options
Gilead, Merck sign pact to develop, commercialise long-acting HIV treatment combinations
Collaboration to focus on oral and injectable formulations of Lenacapavir and Islatravir